{"id":"darunavir-drv-tmc114","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1323","moleculeType":"Small molecule","molecularWeight":"547.67"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Darunavir works by binding to the protease enzyme, which is essential for the maturation of viral particles. By inhibiting this enzyme, darunavir prevents the production of infectious viral particles, thereby reducing the viral load in the body.","oneSentence":"Darunavir is a protease inhibitor that blocks the protease enzyme in HIV, preventing viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:40.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and children"},{"name":"Prevention of HIV-1 infection in adults and children"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT06139796","phase":"PHASE1, PHASE2","title":"Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV","status":"WITHDRAWN","sponsor":"PENTA Foundation","startDate":"2025-02-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT06005610","phase":"PHASE2","title":"Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-04","conditions":"HIV I Infection","enrollment":93},{"nctId":"NCT06747507","phase":"PHASE3","title":"Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance","status":"RECRUITING","sponsor":"University of Nairobi","startDate":"2025-09-01","conditions":"HIV-1-infection","enrollment":392},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT06787976","phase":"PHASE4","title":"Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.","status":"NOT_YET_RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-06-19","conditions":"HIV, Insomnia, Anxiety","enrollment":140},{"nctId":"NCT06907056","phase":"PHASE4","title":"Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2023-11-09","conditions":"HIV Infection","enrollment":138},{"nctId":"NCT03123848","phase":"PHASE4","title":"A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2017-04-14","conditions":"Healthy","enrollment":8},{"nctId":"NCT03227861","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2017-07-31","conditions":"HIV-1","enrollment":109},{"nctId":"NCT02578550","phase":"PHASE1","title":"A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-11","conditions":"Healthy","enrollment":126},{"nctId":"NCT04718805","phase":"PHASE1","title":"A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-01-26","conditions":"Healthy","enrollment":22},{"nctId":"NCT04661397","phase":"PHASE1","title":"A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-01-05","conditions":"Healthy","enrollment":37},{"nctId":"NCT02984852","phase":"PHASE1","title":"Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-12","conditions":"Healthy","enrollment":30},{"nctId":"NCT04208061","phase":"PHASE1","title":"A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-18","conditions":"Healthy","enrollment":28},{"nctId":"NCT03675815","phase":"PHASE4","title":"Body Composition Sub-study of the D2EFT Trial","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-12-05","conditions":"HIV Infections","enrollment":155},{"nctId":"NCT06676410","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants","status":"RECRUITING","sponsor":"Code Pharma","startDate":"2023-07-20","conditions":"HIV, HIV Infection","enrollment":40},{"nctId":"NCT01400412","phase":"PHASE2","title":"Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-01-17","conditions":"HIV-1 Infection","enrollment":262},{"nctId":"NCT03577470","phase":"","title":"An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2018-06-13","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":246},{"nctId":"NCT02735863","phase":"PHASE2","title":"ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2016-05","conditions":"HIV Infection","enrollment":30},{"nctId":"NCT04630002","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-10-28","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":"HIV","enrollment":""},{"nctId":"NCT05197075","phase":"PHASE1","title":"A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-03","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":15},{"nctId":"NCT01281813","phase":"PHASE3","title":"TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2011-08-08","conditions":"HIV-1 Infections","enrollment":145},{"nctId":"NCT05378906","phase":"PHASE1","title":"A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-07","conditions":"Healthy","enrollment":32},{"nctId":"NCT02431247","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-07-06","conditions":"Immunodeficiency Virus Type 1, Human","enrollment":725},{"nctId":"NCT03685500","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2018-12-04","conditions":"HIV Infections","enrollment":78},{"nctId":"NCT04901728","phase":"","title":"Patients' Experiences and Perceptions of 3TC/DTG Dual Therapy (the PEDAL Study)","status":"UNKNOWN","sponsor":"University of Sussex","startDate":"2021-07-01","conditions":"HIV Infections","enrollment":118},{"nctId":"NCT02771249","phase":"PHASE1","title":"Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2016-06-03","conditions":"HIV Infected Population With Latent Tuberculosis","enrollment":37},{"nctId":"NCT03683524","phase":"PHASE4","title":"EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2018-11-19","conditions":"HIV-1 Infection","enrollment":96},{"nctId":"NCT02269917","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2015-03","conditions":"Human Immunodeficiency Virus Type 1","enrollment":1149},{"nctId":"NCT00260078","phase":"PHASE1, PHASE2","title":"Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03447873","phase":"PHASE4","title":"Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)","status":"COMPLETED","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2017-06-01","conditions":"HIV Infections","enrollment":153},{"nctId":"NCT02738502","phase":"PHASE2","title":"Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-07-06","conditions":"Maternal-fetal Infection Transmission","enrollment":91},{"nctId":"NCT02499978","phase":"PHASE2, PHASE3","title":"Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2016-05","conditions":"HIV/AIDS","enrollment":""},{"nctId":"NCT02383108","phase":"PHASE2, PHASE3","title":"Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2016-06","conditions":"HIV Infection","enrollment":318},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT03472326","phase":"PHASE2","title":"Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2018-04-03","conditions":"HIV-1-infection","enrollment":21},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT04236453","phase":"PHASE1","title":"A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents","status":"TERMINATED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-01-23","conditions":"Healthy","enrollment":16},{"nctId":"NCT01792570","phase":"PHASE3","title":"DRV/r + RPV QD: Efficacy and Toxicity Reduction","status":"COMPLETED","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2014-09-30","conditions":"Human Immunodeficiency Virus","enrollment":37},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT03042390","phase":"","title":"Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2016-12-23","conditions":"HIV Infections","enrollment":762},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01258374","phase":"","title":"Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2010-05","conditions":"Integrase Inhibitors, HIV; HIV PROTEASE INHIB","enrollment":15},{"nctId":"NCT04064632","phase":"PHASE4","title":"RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection","status":"UNKNOWN","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2017-02-01","conditions":"HIV Infection","enrollment":1609},{"nctId":"NCT02993237","phase":"PHASE1","title":"Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-01-23","conditions":"HIV-1","enrollment":27},{"nctId":"NCT01138605","phase":"PHASE2","title":"TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2010-10-13","conditions":"HIV-1 Infections","enrollment":46},{"nctId":"NCT01900106","phase":"PHASE3","title":"A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)","status":"COMPLETED","sponsor":"University of Modena and Reggio Emilia","startDate":"2013-11","conditions":"HIV Infection","enrollment":47},{"nctId":"NCT03892161","phase":"PHASE1","title":"Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers","status":"TERMINATED","sponsor":"University of Cape Town","startDate":"2018-04-12","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT03589027","phase":"PHASE2","title":"Darunavir and Rilpivirine Interactions With Levonorgestrel Implant","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2018-08-07","conditions":"HIV-1-infection, Contraception","enrollment":60},{"nctId":"NCT03589040","phase":"PHASE2","title":"Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2018-09-25","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT03842488","phase":"PHASE4","title":"Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2019-04","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT01968551","phase":"PHASE3","title":"Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-03","conditions":"HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":158},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00830804","phase":"PHASE2","title":"Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-04","conditions":"HIV-1 Infections","enrollment":113},{"nctId":"NCT02337322","phase":"PHASE4","title":"Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir","status":"UNKNOWN","sponsor":"Juan A. Arnaiz","startDate":"2015-03-31","conditions":"Acquired Immune Deficiency Syndrome Virus","enrollment":104},{"nctId":"NCT02671383","phase":"PHASE3","title":"Evaluation of Low-dose Darunavir in a Switch Study","status":"COMPLETED","sponsor":"Willem Daniel Francois Venter","startDate":"2016-06-30","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT02926456","phase":"","title":"Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2016-07-22","conditions":"Human Immunodeficiency Virus","enrollment":337},{"nctId":"NCT02818348","phase":"PHASE1","title":"Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2016-06","conditions":"HIV-1 Infection","enrollment":30},{"nctId":"NCT02277600","phase":"PHASE1","title":"A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-11-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":32},{"nctId":"NCT01449929","phase":"PHASE3","title":"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-10-31","conditions":"Infection, Human Immunodeficiency Virus","enrollment":488},{"nctId":"NCT01928407","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts","status":"COMPLETED","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2011-02-23","conditions":"HIV-1 Infection, Immunosuppression-related Infectious Disease","enrollment":120},{"nctId":"NCT01448707","phase":"PHASE3","title":"A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-03-15","conditions":"Human Immunodeficiency Virus (HIV) Infections, Acquired Immunodeficiency Syndrome (AIDS) Virus","enrollment":274},{"nctId":"NCT02475135","phase":"PHASE1","title":"Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-06-01","conditions":"Healthy","enrollment":72},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT02063360","phase":"PHASE1","title":"DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-02-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":42},{"nctId":"NCT01905059","phase":"PHASE3","title":"Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-02","conditions":"HIV Infection","enrollment":265},{"nctId":"NCT00543101","phase":"PHASE4","title":"Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2007-10","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT01440569","phase":"PHASE3","title":"Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-09","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":314},{"nctId":"NCT01475838","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-11","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":438},{"nctId":"NCT01363011","phase":"PHASE3","title":"Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-05","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":106},{"nctId":"NCT01565850","phase":"PHASE2","title":"D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-04","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":153},{"nctId":"NCT00851799","phase":"","title":"Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-06","conditions":"HIV Infection","enrollment":334},{"nctId":"NCT00977756","phase":"","title":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2002-08","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT01374802","phase":"PHASE1","title":"Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-06","conditions":"HIV Infections","enrollment":14},{"nctId":"NCT00665847","phase":"PHASE2","title":"TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-11","conditions":"HIV-1","enrollment":103},{"nctId":"NCT01258439","phase":"PHASE4","title":"Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.","status":"COMPLETED","sponsor":"St Vincent's Hospital, Sydney","startDate":"2010-11","conditions":"HIV, Cardiovascular Disease","enrollment":25},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00811954","phase":"PHASE3","title":"Comparative Study of Three NNRTI-Sparing HAART Regimens","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-05","conditions":"HIV Infection","enrollment":1814},{"nctId":"NCT01254656","phase":"PHASE2","title":"A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-02","conditions":"HIV-1","enrollment":108},{"nctId":"NCT00517192","phase":"PHASE3","title":"Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00919854","phase":"PHASE2","title":"A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-09","conditions":"Human Immunodeficiency Virus 1","enrollment":27},{"nctId":"NCT02097381","phase":"NA","title":"Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2010-04","conditions":"HIV Infection","enrollment":10},{"nctId":"NCT01308658","phase":"PHASE1","title":"TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2011-01","conditions":"Healthy","enrollment":128},{"nctId":"NCT01199939","phase":"PHASE2","title":"A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2010-05","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":54},{"nctId":"NCT01541085","phase":"","title":"An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2011-12","conditions":"Human Immunodeficiency Virus; HIV","enrollment":33},{"nctId":"NCT01052883","phase":"PHASE1","title":"TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-03","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT01391013","phase":"PHASE2","title":"A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2009-06","conditions":"Human Immunodeficiency Virus 1","enrollment":30},{"nctId":"NCT01876966","phase":"PHASE1","title":"Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2011-03","conditions":"HIV","enrollment":33},{"nctId":"NCT00524368","phase":"PHASE3","title":"A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2007-10","conditions":"Human Immunodeficiency Virus - Type 1","enrollment":590}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"darunavir (DRV, TMC114)","genericName":"darunavir (DRV, TMC114)","companyName":"Janssen-Cilag International NV","companyId":"janssen-cilag-international-nv","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darunavir is a protease inhibitor that blocks the protease enzyme in HIV, preventing viral replication. Used for Treatment of HIV-1 infection in adults and children, Prevention of HIV-1 infection in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}